Anika Therapeutics (ANIK) Other Accumulated Expenses (2011 - 2026)

Anika Therapeutics (ANIK) has reported Other Accumulated Expenses for 15 consecutive years, with $326000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses fell 49.14% year-over-year to $326000.0 in Q2 2026; TTM through Jun 2026 was $326000.0, a 49.14% decrease from a year earlier, with the FY2025 full-year figure at $468000.0, down 38.82% from the prior year.
• Other Accumulated Expenses was $326000.0 for Q2 2026 at Anika Therapeutics, down from $479000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.1 million in Q1 2022 and troughed at $326000.0 in Q2 2026.
• A 5-year average of $596055.6 and a median of $515000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses sank 97.14% in 2022 and jumped 126.33% in 2024, its largest moves.
• Over 5 years, Other Accumulated Expenses stood at $510000.0 in 2022, then tumbled by 33.73% to $338000.0 in 2023, then soared by 126.33% to $765000.0 in 2024, then sank by 38.82% to $468000.0 in 2025, then tumbled by 30.34% to $326000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $326000.0 (Q2 2026), $479000.0 (Q1 2026), and $468000.0 (Q4 2025), per Business Quant data.